Flow Forward Medical boosted its latest funding round to further develop its device that helps improve outcomes for hemodialysis patients.
The Olathe-based company closed a $1.3 million round of additional Series A financing led by the Kansas Bioscience Authority. Flow Forward previously raised $4.4 million, bringing its total funding raised to date to about $5.7 million.
Flow Forward created the AFE blood pump system, which is designed for temporary use to quickly dilate peripheral veins through flow-mediated vascular remodeling prior to arteriovenous fistula surgery. In addition to mitigating care costs, the device reduces morbidity and mortality in hemodialysis patients.
Flow Forward also announced that it will receive a $225,000 Phase I Small Business Innovation Research grant from the National Institutes of Health. The grant will help fund testing on peripheral vein dilation with the AFE System prior to AVF creation in a nonclinical model.
Flow Forward is a spinoff of CEO Nick Franano’s previous company, Novita Therapeutics. To learn more on Flow Forward and its device, click here.